China Medical GatewayLoading your healthcare gateway…

Lin Yan Song

Lin Yan Song — Chief Physician — Department of Nuclear Medicine — Peking Union Medical College Hospital

Specialties

Radionuclide diagnosis and treatment of thyroid diseases such as (Graves' hyperthyroidism, thyroid cancer).

Education

From September 1985 to July 1990, he studied in the undergraduate program of Medicine at Bethune Medical University. From September 1990 to July 1993, he studied in the Neurophysiology program at Bethune Medical University and obtained a Master's degree. From September 1993 to July 1996, he studied in the Nuclear Medicine program at Huashan Hospital of Shanghai Medical University and obtained a Doctoral degree. From November 1998 to November 2000, he completed postdoctoral research at the Clinical Medicine Postdoctoral Mobile Station of Peking Union Medical College.

Professional Experience

Lin Yansong, member of the Jiusan Society, holds a PhD and postdoctoral degree in Nuclear Medicine, is a chief physician, deputy director of the Department of Nuclear Medicine at Peking Union Medical College Hospital, and a doctoral supervisor in the field of Nuclear Medicine at the Chinese Academy of Medical Sciences, Peking Union Medical College. From September 1996 to October 1998, he served as an attending physician in the Department of Nuclear Medicine at the Affiliated Hospital of Qingdao University Medical College. From December 2000 to October 2009, he served as associate chief physician and master’s supervisor at the Department of Nuclear Medicine, Peking Union Medical College Hospital. Since October 2009, he has served as chief physician and doctoral supervisor at the same department. As chief editor, he completed the "Consensus on Diagnosis and Treatment of Recurrent and Metastatic Differentiated Thyroid Cancer" and the "Thyroid Cancer Patient Education Handbook." As a primary author, he successively completed China’s "Expert Consensus on 131I Treatment of Graves' Hyperthyroidism 2010 Edition," "Guidelines for Diagnosis and Treatment of Thyroid Nodules and Differentiated Thyroid Cancer 2012," "Guidelines for 131I Treatment of Graves' Hyperthyroidism 2013 Edition," "Guidelines for 131I Treatment of Differentiated Thyroid Cancer 2014 Edition," "Consensus on Diagnosis and Treatment of Recurrent and Metastatic Differentiated Thyroid Cancer," and "Guidelines for the Management of Persistent/Recurrent and Metastatic Thyroid Cancer." Since 2002, as a member of the Ministry of Health Professional Technical Title Examination Expert Committee, he has regularly participated in setting and reviewing exam questions for intermediate, associate, and senior professional titles organized by the Ministry of Health every year. He has led projects that have received funding from the National Natural Science Foundation of China five times and currently has two ongoing research projects. As the first completer, he has won the Chinese Medical Science and Technology Award twice (in 2006 and 2015) and the Peking Union Medical College Hospital Medical Achievement Award three times (in 2012, 2015, and 2016). As PI, he has led multiple domestic and international single- and multi-center clinical trials studying targeted drugs such as sorafenib, vandetanib, apatinib, donafenib, and lenvatinib for the treatment of iodine-refractory differentiated thyroid cancer. As a doctoral supervisor, he has guided three doctoral students and eighteen master's students, with twelve having graduated.

Professional Roles

He serves as the Chairman of the Thyroid Cancer Professional Committee of the Chinese Society of Clinical Oncology (CSCO), Deputy Head of the Therapeutics Group of the Nuclear Medicine Branch of the Chinese Medical Association, Deputy Chairman of the Thyroid Disease Professional Committee of the China Association for International Exchange of Medical and Health Care, Deputy Chairman of the Molecular Diagnostics Professional Committee of the China Research Hospital Association, Standing Committee Member and Head of the Therapeutics Group of the Beijing Nuclear Medicine Branch, Standing Committee Member of the Thyroid Cancer Professional Committee of the Chinese Anti-Cancer Association, and Member of the Thyroid Cancer Committee of the Chinese Medical Doctor Association of Surgery. He also serves as an editorial board member of the Chinese Journal of Nuclear Medicine and Molecular Imaging, Chinese Journal of Cancer Prevention and Treatment, and Chinese Journal of Cancer, an expert of the Professional Technical Title Examination Expert Committee of the Ministry of Health, and China Coordinator for the International Atomic Energy Agency (IAEA) RAS6074 & RAS6083 projects.

Return to Home